Summit's Cancer Drug Delays Progression — But The FDA Rejects Its Lung-Cancer Application

Ivonescimab missed the trial's main survival goal, while Summit plans to keep developing the drug across other cancers.

Share
Summit's Cancer Drug Delays Progression — But The FDA Rejects Its Lung-Cancer Application

Summit Therapeutics, which develops cancer medicines, said Sunday the FDA rejected its application for ivonescimab plus chemotherapy in lung cancer because the trial did not establish a statistically significant survival benefit. The treatment delayed disease progression, but regulators judged that evidence insufficient to support approval, according to the company's SEC filing filed Monday.

Progression Gains Fell Short

The application sought approval for patients with locally advanced or metastatic non-small cell lung cancer who had already received EGFR-targeted therapy. The FDA's complete response letter means the application cannot be approved as submitted.

The global late-stage study, HARMONi, randomly assigned patients to ivonescimab plus platinum chemotherapy or placebo plus platinum chemotherapy. Neither patients nor investigators knew which treatment patients received. Participants had EGFR-mutated, non-squamous disease and had previously received a third-generation EGFR-targeted drug.

The trial had two main goals: delaying progression and extending survival. It met the progression goal but missed the survival goal. Summit's Sunday announcement said the FDA concluded the progression benefit alone did not establish that the treatment's benefits outweighed its risks.

Summit said a later analysis, conducted after the original analysis, produced a survival hazard ratio of 0.76 across the overall, Asian and western patient populations. That follow-up evidence did not change the rejection. Summit also said no FDA-approved regimen has demonstrated a statistically significant survival benefit in this particular patient setting.

Treatment-related adverse events led 16 patients, or 7.3%, to stop ivonescimab, versus 11 patients, or 5.0%, who stopped placebo. Such events caused four deaths, or 1.8%, in the ivonescimab group and five deaths, or 2.3%, in the comparison group.

A China Approval, A U.S. Setback

Summit's approval effort traces to its 2022 partnership with Akeso, which developed ivonescimab and sells it in China. Chinese authorization for this lung-cancer setting came in May 2024. Summit submitted additional survival data to the FDA in September.

Ivonescimab is an antibody designed to block PD-1 and VEGF in one molecule. Summit licensed development and sales rights covering the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. The drug remains investigational throughout Summit's licensed territories, and the company has no approved products.

Before the rejection, Summit had parted ways with chief commercial officer Robert LaCaze and several senior leaders working on launch preparations.

The Broader Ivonescimab Bet

Robert W. Duggan, Summit's chairman and co-chief executive, pledged to press ahead: "we will continue through our expansive clinical development program."

Summit's other studies include late-stage trials in previously untreated metastatic lung cancer and colorectal cancer. It is also testing combinations in urothelial cancer and clear cell renal cancer, with additional cooperative-group studies addressing head-and-neck cancer and biliary tract cancer.

The company plans combination trials with AstraZeneca and Daiichi Sankyo using Datroway in breast and lung cancer, including a late-stage study in previously untreated triple-negative breast cancer. Other collaborations involve AstraZeneca in gastrointestinal tumors, Revolution Medicines and GSK in solid tumors, and Arcus Biosciences in clear cell renal cancer.

The rejection blocks this lung-cancer application in its current form; Summit's broader ivonescimab program continues.

Sources

More on Summit Therapeutics

All Summit Therapeutics (SMMT) coverage →